- Support Forum
- Main Forum
- Media & News
- Australian PBS Listing
- Zepatier - PBAC yes for GT1 but no for GT3
Zepatier - PBAC yes for GT1 but no for GT3
The Pharmaceutical Benefits Advisory Committee (PBAC) has agreed there is a need for interferon-free treatment regimens for people with hepatitis C – genotypes 4 and 6. At its July meeting PBAC recommended that the combination of grazoprevir + elbasvir (Zepatier®) be listed on the Pharmaceutical Benefits Scheme (PBS). It was also recommended as a further option for people with genotype 1. Merck Sharpe and Dohme, who produce the medicine, also sought PBS listing for genotype 3 but PBAC considered there was insufficient data to support use with genotype 3 at this time. [which is a damn pity because Canada disagrees]
YMMV
Please Log in or Create an account to join the conversation.
That is wonderful news for genotypes 4 and 6 including G1's but it seems so very unfair for those with G3. Where is the dislike tab?
gt 1a VL 6m
F2/3 FibroScan - 9KPa in 2011 and 7KPa in 2015
sof/dac 10 December for 12 weeks
pre tx alt 85 ast 51
4 wk alt 34 ast 31 UND <35
8 wk alt 29 ast 32 UND <15
12wk alt 25 ast 25 EOT 3.3.16
SVR24 UND KPa5.3 F0 in normal range
I am well
.forever grateful to fixhepc
Please Log in or Create an account to join the conversation.
- Paul-Jarman-facebook
-
Moderator
- Offline
- Moderator
-
- The gypsy woman told my mother Before I was born
- Posts: 383
- Thank you received: 659
Maybe it's possible that Zepatier could interfere with the PBAC's deal with Gilead and funding caps given that G3 is more prevelant here.
Two time relapser.
SVR 4 achieved 12/16 at last
SVR 12 achieved 22/02/2017 The Bastard has been defeated



GT 3 - about 28 yrs with HCV
Please Log in or Create an account to join the conversation.
- Support Forum
- Main Forum
- Media & News
- Australian PBS Listing
- Zepatier - PBAC yes for GT1 but no for GT3